Pharma BD Deal Intelligence
BMS acquired MyoKardia in November 2020 for $13.1 billion (all-cash, $225/share) to obtain mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy. The thesis on a pre-revenue cardiovascular asset has been validated: launched as Camzyos after FDA approval in April 2022, the drug crossed blockbuster status with full-year 2025 revenue above $1 billion (Q4 2025 $353M, +77% YoY). An April 2025 FDA label simplification cut echo-monitoring burden and removed key contraindications, broadening the eligible population. The upside is now capped on two fronts: a 2025 Phase III failure in non-obstructive HCM removed a major expansion indication, and Cytokinetics' rival cardiac myosin inhibitor aficamten (Myqorzo) won FDA approval in December 2025, introducing the first direct class competitor in obstructive HCM.